Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial
Affiliation
Cancer Research UK and University College London Cancer Trials Centre , London , UKIssue Date
2019
Metadata
Show full item recordCitation
Phillips EH, Devereux S, Radford J, Mir N, Adedayo T, Clifton-Hadley L, et al. Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial. Leuk Lymphoma. 2019 Feb 18:1-4.Journal
Leukemia & LymphomaDOI
10.1080/10428194.2019.1576870PubMed ID
30773077Additional Links
https://dx.doi.org/10.1080/10428194.2019.1576870Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1080/10428194.2019.1576870